Conference Correspondent
Selinexor, pomalidomide, and dexamethasone led to high response rates in patients with multiple myeloma who were refractory to lenalidomide and had not been previously treated with pomalidomide. Read More ›

After more than 4 years of median follow-up, treatment with daratumumab, lenalidomide, and dexamethasone continues to improve progression-free survival compared with lenalidomide and dexamethasone alone in relapsed/refractory multiple myeloma, with deep and durable responses. Read More ›

Despite safety concerns related to daratumumab, a meta-analysis of 5 large randomized controlled trials showed no significant increase in treatment delays, trial discontinuation, or treatment-related deaths in patients with untreated or relapsed/refractory multiple myeloma who received the drug. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

A groundbreaking report presented today at ESMO conveyed data from an interim analysis of a phase 2b trial demonstrating that the combination of NPS + trastuzumab is safe and may provide clinically meaningful benefit to women with HER2 low-expressing breast cancer, with a particularly marked benefit in the subgroup with triple-negative breast cancer. Read More ›

Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early. Read More ›

The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity. Read More ›

Although the combination of 2 antivascular agents showed preliminary efficacy, increased cardiac toxicity has resulted in premature discontinuation of the trial. Read More ›

In a prospective trial, the VEGFR-2 small-molecule inhibitor apatinib has shown promising efficacy and safety signals. Read More ›

Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established. Read More ›

Page 13 of 31


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: